Clinical Trials
38 trialsPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
EvoPAR-PR02
AstraZeneca
RADVAN
Sun Yat-sen University
TITAN
Aragon Pharmaceuticals, Inc.
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
PROTEUS
Janssen Research & Development, LLC
KEYNOTE-991
Merck Sharp & Dohme LLC
GETUG-AFU 40
UNICANCER
China ARCHES
Astellas Pharma Inc
ASCENDE-SBRT
Canadian Cancer Trials Group
LIBERTAS
Janssen Research & Development, LLC
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
ARANOTE
Bayer
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
CHAARTED
Eastern Cooperative Oncology Group
ARASENS
Bayer
Apa/Enza-short
Erasmus Medical Center
KEYNOTE-991
Merck Sharp & Dohme LLC
STAMPEDE2
University College, London
PEACE 7
UNICANCER
ARASAFE
Jena University Hospital
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Janssen Research & Development, LLC
mCRPC
Fudan University
PEACE8
UNICANCER
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
Sir Mortimer B. Davis - Jewish General Hospital
PEACE1
UNICANCER
SPARKLE
Universitaire Ziekenhuizen KU Leuven
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14
Göteborg University
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
UNICANCER
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
SensiCab
Örebro University, Sweden
ZAPCA
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Post-operative or Early Salvage XRT and ADT for High Risk PCa
European Organisation for Research and Treatment of Cancer - EORTC
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Novartis
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)